# Vistusertib

Source: https://onco.cc/drugs/vistusertib/  
OnCo record `vistusertib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Vistusertib is an oral serine/threonine kinase inhibitor from AstraZeneca, in registered phase 2 trials for non-small-cell lung cancer, small-cell lung cancer.

## Summary

Vistusertib is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by AstraZeneca, in non-small-cell lung cancer, small-cell lung cancer. A serine/threonine kinase inhibitor: the name stem -sertib marks a small molecule that blocks a kinase in this family. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Modality: Oral serine/threonine kinase inhibitor
- Mechanism: A serine/threonine kinase inhibitor: the name stem -sertib marks a small molecule that blocks a kinase in this family.

## Sources

- ClinicalTrials.gov: trials of Vistusertib: https://clinicaltrials.gov/search?intr=Vistusertib

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- trials: [Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy](https://onco.cc/trials/nct03334617/)

---
JSON: https://onco.cc/api/v1/entities/vistusertib.json